New epilepsy drug shows promise in Long-Term safety trial

NCT ID NCT07238868

Recruiting now Disease control Sponsor: Shanghai Zhimeng Biopharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an investigational drug called CB03-154 in 144 people with focal epilepsy. Participants take the drug for up to two years to see if it is safe and helps reduce seizures. The goal is to find a better long-term treatment option for epilepsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CB03-154
What this could lead to: If successful, this could provide a new long-term treatment option to reduce seizure frequency in people with focal epilepsy.
What could go wrong: This is an early Phase 2 open-label study, so results may not confirm effectiveness. Side effects or lack of seizure control could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCAL EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

focal epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCAL EPILEPSY

Contacts and locations

Locations

Alfred Health
RECRUITING

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.